Associate Scientist, Protein Biochemistry (South San Francisco, CA)

Sutro Biopharma, Inc. is looking for an Associate Scientist to work with our novel cell free protein production platform (XpressCF) as part of our Protein Biochemistry Research group. This position will include protein expression to support the drug development pipeline as well as characterization and engineering of the XpressCF system to improve titers and robustness. This position will collaborate closely in cross functional teams within the research, pre-clinical, process development, and platform improvement groups.


  • Cell-free protein expression to support research and pre-clinical stage projects.
  • Early-stage process development of lead molecules to improve titer and robustness.
  • Characterization and engineering of the cell free system for platform improvement.
  • Design and execute experiments at scales ranging from plate based high-throughput formats to benchtop bioreactors.
  • Characterization of reaction output and intermediates, eg. SDS-PAGE, enzymatic assays, and RP-HPLC. 


  • Ph.D. with 0-2 years of industry experience or M.S./B.S. with 5-7 years of experience in Biochemistry, Bioengineering, Chemical Engineering, Synthetic Biology, or a related discipline.
  • Thorough understanding of protein expression, purification, and characterization.
  • Basic knowledge of bacterial metabolism.
  • Experience with cell free protein synthesis and/or in vitro enzyme assays is preferred. 

Sound exciting? Apply today and join our team! 

Please submit resume for Req. #2267 to Please visit our website at for more information.

Sutro Biopharma, Inc. requires all new hires to be fully vaccinated for COVID-19 prior to the first date of employment.  As required by applicable law, Sutro will consider requests for reasonable accommodations.

Sutro provides a competitive benefits package that includes a choice of health, dental, and vision insurance, life insurance, flexible spending accounts, 401K plan, PTO, ESPP (Employee Stock Purchase Plan) and stock options.

As an equal opportunity employer, we believe in fostering a culture that is inclusive and values diversity in background and opinions. Sutro Biopharma hires extraordinary individuals into every position in the company and is committed to the diversity of our team. Our company progresses without regard of race, ethnicity, gender, sexual orientation, religious belief, age, disability, or citizenship status. We are dedicated to creating a safe environment where our employees can grow and succeed together. 

Salaries listed on jobsites may not be representative of salary ranges at Sutro Biopharma.

We look forward to hearing from candidates who are interested in exploring opportunities with Sutro! Our People & Culture team/hiring managers are unable to respond and do not accept solicitations from third-party agencies.

Company Overview 

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development, and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro’s platform has led to cytokine-based immuno-oncology therapies, ADCs, vaccines, and bispecific antibodies directed at precedented targets in clinical indications where the current standard of care is suboptimal.

The platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.

In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics. As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to kill tumors more efficiently without harming healthy cells.